<mods:mods version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" xmlns:mods="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><mods:titleInfo><mods:title>VITILIGODA MELANOTSITLARNI AUTOIMMUN DESTRUKSIYASI: IL-23/IL-17 YO‘LI ASOSIDA TAHLIL</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Axror Turaqulovich</mods:namePart><mods:namePart type="family">Tog‘ayev</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Sodiqov Boymurod Panji</mods:namePart><mods:namePart type="family">o‘g‘li</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Vitiligo — surunkali, qaytuvchan kechuvchi, immun mexanizmlar bilan bog‘liq teri rang yo‘qolishi bilan kechadigan dermatoz bo‘lib, uning asosiy patogenetik mexanizmlaridan biri melanotsitlarning autoimmun yo‘l bilan destruksiyasi hisoblanadi. Kasallikning asosiy klinik belgisi — terining turli qismlarida chegaralangan yoki tarqalgan oq dog‘larning paydo bo‘lishidir. So‘nggi yillarda olib borilgan immunologik tadqiqotlar natijasida vitiligo patogenezida IL-23/IL-17 yo‘lining faolligi muhim o‘rin tutishi aniqlangan. Ushbu yo‘l Th17 limfotsitlarining differensiasiyasi va ularning sitokin ishlab chiqarish faolligini boshqaradi. IL-23 sitokini Th17 hujayralarining proliferatsiyasini kuchaytirib, IL-17A va IL-22 orqali melanotsitlarga sitotoksik ta’sir ko‘rsatadi.</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2025-11-20</mods:dateIssued></mods:originInfo><mods:originInfo><mods:publisher>"Research Science and Innovation house" LLC</mods:publisher></mods:originInfo><mods:genre>Maqola</mods:genre></mods:mods>